ENDPOINTS NEWS4h
Syn­dax's Re­vu­forj wins FDA ap­proval in ag­gres­sive form of leukemia
Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...
Syndax Pharmaceuticals Gains Buy Rating Boost from Revuforj’s Early Approval and Strategic Launch Plan
Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...
No bail to jumbo Covid centre case accused
A special PMLA court denied bail to Sujit Patkar, linked to Shiv Sena leader Sanjay Raut, for alleged Covid centre irregularities and fraud.
BioPharma Dive7h
Syndax secures FDA OK for new kind of leukemia drug
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
Syndax Pharmaceuticals Gains ‘Buy’ Rating Amidst Revuforj’s FDA Approval and Promising Market Prospects
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
Medscape11h
Revumenib Approved for R/R Acute Leukemia With KMT2A Translocation
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...